ANTONIO JOSÉ
CARUZ ARCOS
CATEDRATICO DE UNIVERSIDAD
Hospital Universitario de Valme
Sevilla, EspañaHospital Universitario de Valme -ko ikertzaileekin lankidetzan egindako argitalpenak (32)
2022
-
IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men
Virulence, Vol. 13, Núm. 1, pp. 757-763
2021
-
Cd46 genetic variability and hiv-1 infection susceptibility
Cells, Vol. 10, Núm. 11
2020
-
Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine
AIDS, Vol. 34, Núm. 1, pp. 25-32
-
Toll-Like Receptor 2 Promoter -196 to -174 Deletion Affects CD4 Levels Along Human Immunodeficiency Virus Infection Progression
The Journal of infectious diseases, Vol. 222, Núm. 12, pp. 2007-2011
2019
-
Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability
Infection, Genetics and Evolution, Vol. 73, pp. 276-286
-
Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection
Scientific Reports, Vol. 9, Núm. 1
2015
-
Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2171-2175
2014
-
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
Liver International, Vol. 34, Núm. 4, pp. 558-566
-
Association of low-density lipoprotein receptor genotypes with hepatitis C viral load
Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24
-
IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
PLoS ONE, Vol. 9, Núm. 4
2013
-
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921
-
Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection
Journal of Infectious Diseases, Vol. 207, Núm. 3, pp. 411-419
-
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
Infection, Vol. 41, Núm. 1, pp. 21-26
-
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435
-
Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients
PLoS ONE, Vol. 8, Núm. 4
-
Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response
Journal of Infection, Vol. 67, Núm. 1, pp. 59-64
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
-
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection
AIDS, Vol. 27, Núm. 17, pp. 2715-2724
2012
-
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4
Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205
-
Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
PLoS ONE, Vol. 7, Núm. 11